IRIS
AGUSTONI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.176
AS - Asia 1.435
EU - Europa 997
SA - Sud America 228
AF - Africa 88
Continente sconosciuto - Info sul continente non disponibili 81
OC - Oceania 2
Totale 5.007
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.025
SG - Singapore 458
CN - Cina 393
IT - Italia 274
HK - Hong Kong 215
RU - Federazione Russa 192
VN - Vietnam 168
BR - Brasile 156
DE - Germania 122
FR - Francia 83
GB - Regno Unito 83
CA - Canada 75
FI - Finlandia 73
ZA - Sudafrica 58
IN - India 46
IE - Irlanda 41
BD - Bangladesh 37
MX - Messico 26
NL - Olanda 26
AR - Argentina 24
PL - Polonia 20
ES - Italia 16
JP - Giappone 16
TR - Turchia 15
IQ - Iraq 14
VE - Venezuela 14
AT - Austria 13
IL - Israele 11
CZ - Repubblica Ceca 10
SE - Svezia 10
CO - Colombia 8
SA - Arabia Saudita 8
UA - Ucraina 8
CR - Costa Rica 7
EC - Ecuador 7
GT - Guatemala 7
MA - Marocco 7
PH - Filippine 7
EE - Estonia 6
PK - Pakistan 6
SV - El Salvador 6
BE - Belgio 5
CL - Cile 5
DZ - Algeria 5
HN - Honduras 5
JM - Giamaica 5
JO - Giordania 5
MY - Malesia 5
PY - Paraguay 5
ID - Indonesia 4
KE - Kenya 4
KG - Kirghizistan 4
LT - Lituania 4
NI - Nicaragua 4
PR - Porto Rico 4
TN - Tunisia 4
UY - Uruguay 4
AZ - Azerbaigian 3
BO - Bolivia 3
CW - ???statistics.table.value.countryCode.CW??? 3
DO - Repubblica Dominicana 3
EG - Egitto 3
LV - Lettonia 3
SC - Seychelles 3
TT - Trinidad e Tobago 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
AU - Australia 2
CH - Svizzera 2
ET - Etiopia 2
GP - Guadalupe 2
KW - Kuwait 2
PA - Panama 2
PE - Perù 2
PT - Portogallo 2
SY - Repubblica araba siriana 2
UZ - Uzbekistan 2
AL - Albania 1
BB - Barbados 1
BH - Bahrain 1
BW - Botswana 1
BY - Bielorussia 1
GE - Georgia 1
HR - Croazia 1
HT - Haiti 1
IR - Iran 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LU - Lussemburgo 1
NP - Nepal 1
OM - Oman 1
RW - Ruanda 1
TH - Thailandia 1
TJ - Tagikistan 1
YE - Yemen 1
Totale 4.929
Salva come PNG Salva come JPEG
Città #
San Jose 327
Singapore 235
Council Bluffs 226
Ashburn 213
Hong Kong 212
Dallas 180
Beijing 112
Boardman 67
Lauterbourg 58
Los Angeles 56
Munich 52
Ho Chi Minh City 51
Johannesburg 48
New York 48
Hanoi 46
Shanghai 42
Dublin 40
Milan 40
Santa Clara 39
Redondo Beach 37
Turku 37
Columbus 36
Helsinki 36
Moscow 36
Rome 26
Phoenix 25
Montreal 19
Pavia 19
São Paulo 19
Frankfurt am Main 18
Warsaw 18
Buffalo 16
Falkenstein 16
London 15
Tokyo 15
Toronto 15
Düsseldorf 14
North Bergen 14
Orem 14
Brooklyn 13
Chennai 13
Chicago 12
Seattle 12
The Dalles 12
Guangzhou 11
Atlanta 10
Boston 10
Manchester 10
Mexico City 10
Palermo 10
Stockholm 10
Nuremberg 9
Baghdad 7
Brno 7
Cesena 7
Da Nang 7
Dhaka 7
Guatemala City 7
Houston 7
Hyderabad 7
Amsterdam 6
Ankara 6
Bắc Ninh 6
Denver 6
Elk Grove Village 6
Hải Dương 6
Querétaro 6
San José 6
San Salvador 6
Amman 5
Cagliari 5
Florence 5
Fortaleza 5
Haiphong 5
Kingston 5
Poplar 5
Rio de Janeiro 5
Tianjin 5
Vancouver 5
Vienna 5
Bishkek 4
Bondo 4
Calgary 4
Changsha 4
Jacksonville 4
Managua 4
Miami 4
Nairobi 4
San Francisco 4
Turin 4
Washington 4
Wuhan 4
Agadir 3
Asunción 3
Belo Horizonte 3
Buenos Aires 3
Charlotte 3
Desio 3
Detroit 3
Durban 3
Totale 2.916
Salva come PNG Salva come JPEG
Nome #
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium 174
Smoking Habit and Respiratory Function Predict Patients' Outcome after Surgery for Lung Cancer, Irrespective of Histotype and Disease Stage 143
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study 131
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up 124
Non-invasive PD-L1 stratification in non-small cell lung cancer using dynamic contrast-enhanced MRI 124
Preliminary report on harmonization of features extraction process using the ComBat tool in the multi-center "Blue Sky Radiomics" study on stage III unresectable NSCLC 119
Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study 116
Integrating data from multidisciplinary Management of Malignant Pleural Mesothelioma: a cohort study 115
Clinical and Biological Variables Influencing Outcome in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1/PD-L1 Antibodies: A Prospective Multicentre Study 109
A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer 109
Local Therapies and Modulation of Tumor Surrounding Stroma in Malignant Pleural Mesothelioma: A Translational Approach 108
Correlation between PD-L1 Expression of Non-Small Cell Lung Cancer and Data from IVIM-DWI Acquired during Magnetic Resonance of the Thorax: Preliminary Results 108
Malignant Pleural Mesothelioma: From Pathophysiology to Innovative Actionable Targets 107
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study 104
From Interconnection between Genes and Microenvironment to Novel Immunotherapeutic Approaches in Upper Gastro-Intestinal Cancers-A Multidisciplinary Perspective 103
Feasibility and safety of extended pleurectomy/decortication for malignant pleural mesothelioma. A single group experience 103
CT Scan-Guided Fine Needle Aspiration Cytology for Lung Cancer Diagnosis through the COVID-19 Pandemic: What We Have Learned 99
Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC) 96
Phase I Clinical Trial on Pleural Mesothelioma Using Neoadjuvant Local Administration of Paclitaxel-Loaded Mesenchymal Stromal Cells (PACLIMES Trial): Study Rationale and Design 88
EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC 86
Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer 86
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry 85
The Role of Native T1 and T2 Mapping Times in Identifying PD-L1 Expression and the Histological Subtype of NSCLCs 84
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 83
Case Report: Epstein-Barr virus negative lymphoepithelioma-like cholangiocarcinoma: a rare tumor that deserves further exploration. Report of a case with distinct genomic and clinical features 80
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study 79
Pleural Mesothelioma: Treatable Traits of a Heterogeneous Disease 79
Nutritional support in lung cancer: Time to combine immunonutrition with immunotherapy? 78
EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis 77
A non-small cell lung cancer fragile elderly patient treated with immunotherapy and non-ablative radiation therapy: a case report of a winning combination 74
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 73
Radiomics features as predictive and prognostic biomarkers in NSCLC 72
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions 72
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program 71
Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling 71
New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists – INTERACTION group 70
Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer 69
A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines 69
Pragmatic Expectancy on Microbiota and Non-Small Cell Lung Cancer: A Narrative Review 68
Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era 67
The Clinical Value of Nutritional Care before and during Active Cancer Treatment 67
The Evolving Landscape of the Molecular Epidemiology of Malignant Pleural Mesothelioma 66
Impact of hyponatremia in a tertiary cancer center: a one-year-survey at National Cancer Institute of Milan 65
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 64
Management of patients with extensive small-cell lung cancer in the immunotherapy era: An Italian consensus through a Delphi approach 61
T-Cell Activation and Maturation at Tumor Site Associated With Objective Response to Ipilimumab in Metastatic Melanoma 60
Rationale and Design of a Single-Arm, Phase 2, Multi-Center Study of Chemo-Immunotherapy Followed by Hypo-Fractionated RT and Maintenance Immunotherapy in Patients With Unresectable Stage III NSCLC: The DEDALUS Trial 58
Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer 55
Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy 55
Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: analysis of 318 patients 51
Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies 50
Epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with EGFR wild-type non-small-cell lung cancer: the never-ending story 49
Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy 49
Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations 49
Indoleamine 2,3-Dioxygenase Expression in Non-Small-Cell Lung Cancer: Analyses of Prevalence, Clinical Correlations and Prognostic Impact 46
Is a Dexamethasone-Sparing Strategy Capable of Preventing Acute and Delayed Emesis Caused by Combined Doxorubicin and Paclitaxel for Breast Cancer? Analysis of a Phase II Trial 44
Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy? 40
Emerging toxicities in the treatment of non-small cell lung cancer: Ocular disorders 40
PACIFIC trial: new perspectives for immunotherapy in lung cancer 39
Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy 39
Palonosetron Plus Dexamethasone in Highly Emetogenic Chemotherapy: Pooled Data from Two Phase III Trials 36
Palonosetron Plus 1-Day Dexamethasone for the Prevention of Nausea and Vomiting Due to Moderately Emetogenic Chemotherapy: Effect of Established Risk Factors on Treatment Outcome in a Phase III Trial 35
Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy 29
Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem 27
Thyroid toxicity in lung cancer patients treated with immune-checkpoint inhibitors: a single-center retrospective analysis 26
Fruquintinib or Regorafenib? A Weighted Toxicity Score Analysis to Facilitate Better Discussions on Toxicity and Benefits in Later-line Colorectal Cancer Treatment 17
Indoleamine 2,3-dioxygenase-1 expression in non-small-cell lung cancer: analyses of prevalence, clinical correlations and prognostic impact in 2 large patient cohorts 17
Totale 5.007
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.452
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.452
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023137 0 0 0 0 8 0 1 3 31 0 79 15
2023/2024343 40 46 29 27 31 69 31 15 0 18 6 31
2024/20251.096 40 45 33 22 11 123 54 62 260 84 121 241
2025/20262.559 203 149 241 315 310 103 377 137 264 193 172 95
2026/2027872 43 180 151 365 133 0 0 0 0 0 0 0
Totale 5.007